secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2024-11-01T23:59:59+00:00
Accession:  0001213900-24-093531
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio Q3 net loss $12.1M; Phase 2 Alzheimer's trial fully enrolled; top-line data Q2 2025
--------------------------------------------------------------------------------

- Net loss $12.1M vs $8.6M Q3 2023; R&D expenses $10.1M (up from $6.0M).
- Cash and equivalents $33.6M as of Sept 30; raised $13.0M in securities purchase agreement.
- Phase 2 AD trial (XPro) fully enrolled with 201 planned patients; top-line data expected Q2 2025.
- INKmune in prostate cancer trial showed safety and NK cell activity in first cohort; highest dose cohort dosing began.
- Received $2.5M R&D rebate from Australia in July.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024093531/0001213900-24-093531-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024093531/ea0219289-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-093531

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer